David Amsellem analyst PIPER SANDLER

Currently out of the existing stock ratings of David Amsellem, 231 are a BUY (73.1%), 74 are a HOLD (23.42%), 11 are a SELL (3.48%).

David Amsellem

Work Performance Price Targets & Ratings Chart

Analyst David Amsellem works at PIPER SANDLER with a stock forecast success ratio of 51.12% fulfilled within 203.57 days on average.

David Amsellem’s has documented 640 price targets and ratings displayed on 37 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ALKS, Alkermes Plc at 01-Apr-2024.

Wall Street Analyst David Amsellem

Analyst best performing recommendations are on REPH (RECRO PHARMA).
The best stock recommendation documented was for HZNP (HORIZON PHARMA PLC) at 12/7/2022. The price target of $110 was fulfilled within 5 days with a profit of $13.7 (14.23%) receiving and performance score of 28.45.

Average potential price target upside

ADMS Adamas Pharmaceuticals AGN Allergan plc AKRX Akorn AMPH Amphastar P AMRX Amneal Pharmaceuticals, . Common Stock ATRS Antares Pharma BDSI BioDelivery Sciences International BHC Bausch Health Companies COLL Collegium Pharmaceutical EGRX Eagle Pharmaceuticals ENDP Endo International PLC HZNP Horizon Pharma PLC INSY INSYS Therapeutics JAZZ Jazz Pharmaceuticals PLC MNK Mallinckrodt plc NBIX Neurocrine Biosciences PCRX Pacira Pharmaceuticals RVNC Revance The SUPN Supernus Pharmaceuticals TEVA Teva Pharma Industries Ltd ADR CARA Cara Therapeutic EVFM Evofem Biosciences OGN Organon OPTN OptiNose REPH Recro Pharma ASRT Assertio Therapeutics VTRS Viatris ALKS Alkermes Plc AVDL Avadel Pharmaceuticals PLC BXRX Baudax Bio  HRMY Harmony Biosciences Holdings NOVN Novan XERS Xeris Pharmaceuticals AXSM Axsome Therapeutics CERE Cerevel Therapeutics Holdings CORT Corcept Therapeutics orporated IRWD Ironwood Pharmaceuticals

Analyst name


Current price target

Potential distance

Previous price target


Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score


2 years 5 months 4 days ago

0/1 (0%)

$34.88 (99.32%)



2 years 6 months 8 days ago

3/7 (42.86%)

$9.25 (194.74%)




$-1.22 (-14.84%)


2 years 6 months 9 days ago

3/8 (37.5%)

$-1.08 (-13.37%)




$0.88 (10.71%)


2 years 6 months 9 days ago

0/7 (0%)

$1.02 (12.62%)



$-2.22 (-27.01%)


2 years 6 months 9 days ago

0/2 (0%)

$3.2 (23.94%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is David Amsellem is most bullish on?

Potential upside of $55.91 has been obtained for JAZZ (JAZZ PHARMACEUTICALS PLC)

Which stock is David Amsellem is most reserved on?

Potential downside of -$39.44 has been obtained for NBIX (NEUROCRINE BIOSCIENCES)

What Year was the first public recommendation made by David Amsellem?

On 2009

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?